NewLink Genetics Corp (NASDAQ:NLNK)

4.63
BATS BZX Real-Time Price
As of 11:40am ET
 +0.04 / +0.87%
Today’s Change
3.75
Today|||52-Week Range
19.47
-42.91%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$291.7M

Company Description

NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.

Contact Information

NewLink Genetics Corp.
2503 South Loop Drive
Ames Iowa 50010
P:(515) 296-5555
Investor Relations:
(515) 598-2555

Employees

Shareholders

Other institutional45.39%
Individual stakeholders21.30%
Mutual fund holders19.29%

Top Executives

Charles J. LinkChairman, Chief Executive & Scientific Officer
Nicholas N. VahanianPresident & Director
John B. HennemanChief Financial Officer, Secretary, CAO & EVP
Eugene P. KennedyChief Medical Officer
Jun ZhaoVice President-Quality & Compliance